

Plasmagen Biosciences launches blood clotting therapy to overcome haemorrhagic cases

Massive bleeding and excessive blood transfusion in liver transplant can result in prolonged ICU/Hospital stay, more septic episodes and higher mortality rate. CSL Behring-manufactured Haemocomplettan® P is a purified human fibrinogen concentrate which rapidly restores haemostasis by providing convenient replacement therapy in patient



Mumbai: Bengaluru based Plasmagen Biosciences Private Limited, launched Haemocomplettan P (Human Fibrinogen Concentrate), a therapy to stop clotting of blood during cardiac and liver transplant

surgeries.

Haemocomplettan P is approved for therapy and prophylaxis of haemorrhagic diathesis in congenital afibrinogenaemia and acquired hypofibrinogenaemia and is manufactured by CSL Behring, a business unit of CSL.

Highlighting the need of such therapy the company stated, approximately one out of every two cardiac surgery patients requires blood transfusion to manage haemorrhage, and over 25 per cent of blood transfusions in hospitals are for liver transplant recipients and Haemocomplettan® P could be used specially for massive haemorrhagic cases.

Whereas delayed control of massive bleeding during cardiac surgery can result in irreversible end-organ damage like renal failure, cardiovascular events like stroke and myocardial injury or even death, accompanied by significantly inflated costs.

Voicing his stance, Dr N Kanagarajan, Senior Consultant Cardiac Anaesthesiologist at the Madras Medical Mission, Chennai said, “Fibrinogen plays a pivotal role in cardiac surgery bleeding, with decreased concentrations contributing to adverse outcomes. Human fibrinogen concentrate (HFC) has demonstrated efficacy in restoring fibrinogen levels, offering potential benefits in reducing bleeding and minimizing the need for intraoperative blood transfusions.”

“The Collaboration of Plasmagen and CSL Behring will not only further open new avenues in different specialties which includes Cardiac, Liver Transplant, Gastroenterology and Pediatrics but also ensure access to quality products with global safety standards in the biopharmaceutical space,” said Vinod Nahar, Managing Director, Plasmagen Biosciences.

News Source:

<https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/plasmagen-biosciences-launches-blood-clotting-therapy-to-overcome-haemorrhagic-cases/111105707>